Simplification to lamivudine, zidovudine, and abacavir therapy: Impact on adherence, clinical outcome, and economic issues;Simplificación con lamivudina, zidovudina y abacavir: Repercusión sobre la adherencia, resultados clínicos e impacto económico

Farmacia Hospitalaria

Volumn 28, Issue 6 SUPPL. 1, 2004, Pages 27-33

  Ibarra Barrueta, Olatz ^a   Martinez Bengoechea M J ^a   Illaro Uranga, A ^a   Lertxundi Etxebarria U ^a   Iglesias Lambarri, A ^a   Santos Ibanez A ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Adherence; Antiretroviral therapy; Clinical outcome; Economic impact; Simplification

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; ARTICLE; CALCULATION; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COSTS AND COST ANALYSIS; DIDEOXYNUCLEOSIDES; HIV INFECTIONS; HUMANS; LAMIVUDINE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; ZIDOVUDINE;

EID: 14644435851     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Negredo Puigmal E. Estrategias de simplificación del tratamiento antirretroviral. AIDS Cyber J 2003; 6 (2): 68-70.
2. th Interscience Conference of Antimicrobial Agents and Chemotherapy. Toronto, Canada 2000. Abst. 699.
3. Carmona A, Knobel H, Guelar A, Graus S, Mateu de A, López-Colones JL, et al. Factors influencing survival in HIV infected patients treated with HAART. 13th Int. AIDS Conference. Durban, South Africa 2000. Abst. TuOrB417.
4. Paterson DL, Swindells S, Mohr J, Brester M, Vergis E, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Inter Med 2000; 133: 21-30.
5. Daar ES, Cohen C, Remien R, Sherer R, Smith K. Improving Adherence to Antiretroviral Therapy. AIDS Read 2003; 13 (2): 81-90.
6. Stone VE. Enhancing adherence to antiretrovirals: strategies and regimens. Med Gen Med 2002; 4 (3): 22.
7. Codina C, Knobel H, Miró JM, Carmona A, García B, Antela A et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretroviral. Farm Hosp 1999; 23 (4): 215-29.
8. Rubio R, Berenguer J, Miró JM, Antela A, Iribarren JA, González J, et al. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002. Enf Infecc Microbiol Clin 2002; 20 (6): 244-303.
9. Ribera E, Aguirrebengoa K, Miralles C, Antela A, Rivero A, Arribas JR. Simplificación del tratamiento antirretroviral. Enferm Infecc Microbiol Clin 2002; 20: 48-57.
10. Ian F. Once-daily HAART: Toward a new treatment paradigm. J AIDS 2002; 3: S10-5.
11. Pollard RB. Can HIV infection be treated successfully with a once-daily regimen? AIDS Read 2002; 12: 489-508.
12. Ena J, Pasquau F. Once-a-Day highly active antiretroviral therapy: a systematic review. CID 2003; 36: 1186-90.
13. Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, et al. Once-a-day highly active antiretroviral therapy in treatment-naïve HIV-1 infected adults in Senegal. AIDS 2003; 17: 1017-22.
14. Molina JM, Fercgak F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, et al. Once-a-day combination therapy with emtricitabine, didanosine and efavirenz in human inmunodeficiency virus-infected patients. J Infect Dis 2000; 182: 599-602.
15. Maggiolo F, Migliorino M, Maserati R, Pan A, Rizzi M, Provettoni G, et al. Virological and inmunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001; 6: 249-53.
16. Staszewski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A. Nevirapine/didanosine/lamivudine once daily in HIV-infected intravenous drug users. Anitiviral Therapy 1998; 3: 55-6.
17. Eron J, Yetzer E, Ruane P, Becker S, Sawyerr GA, Fisher RL, et al. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS 2000; 14 (6): 671-81.
18. Barreiro P, Soriano V, Blanco F, Casimiro C, De la Cruz JJ, González-Lahoz J, et al. Risks and benefits of replacing portease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14: 807-12.
19. Bartlett JA, Ralph D, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15: 1369-77.
20. Clumeck N. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1 infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 1517-26.
21. Codina C, Martínez M, Tuset M, Del Cacho E, Martín MT, Miró JM, et al. Comparación de tres métodos de cálculo de adherencia en pacientes con tratamiento antirretroviral. Enferm Infecc Microbiol Clin 2002; 20: 484-90.
22. Fumaz CR, Tuldra A, Barceló M, Negredo E, Gel S, Arisa ER, et al. Impact of a once-daily three-drug regimen on the quality of life and adherence of HIV-1+ patients with viral load suppression. XIV Int AIDS Conf 2002 Barcelona. Abst. WePeB5834.
23. Smith MF. HIV patients prefer once-daily regimens. XIV Int AIDS Conf 2002 Barcelona. Abst. MoPeB3290.
24. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 2001; 23: 1296-310.
25. Bilbao J, Beobide I, Floristán C, Ibarra O, Quintana A, Santos A. Estudio del grado de adherencia al tratamiento antirretroviral en 3 hospitales de la CAPV en el 2002. VII Congreso Nacional sobre el Sida, Bilbao 2003. Abst EC2p3.
26. Codina Jané C, Tuset Creus M, Ibarra O, Delgado O, Morancho O, García B. Evaluación de un programa de atención farmacéutica dirigid o a mejorar la adherencia al tratamiento antirretroviral. Farm Hosp 2004; 28 (Supl. 1): 19-26.
27. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S. A randomized trial of simplied maintenance therapy with abacavir, lamivudina and zidovudina in human inmunodeficiency virus infection. J Infect Dis 2002; 185: 1251-60.
28. Katlama C. TRIZAL study: switching from successful HAART to Trizivir® (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4 (2): 79-86.